PureTech Health plc
PRTC.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | -0.31 | 1.25 | 0.02 |
| FCF Yield | -26.52% | -15.69% | -20.08% | -14.48% |
| EV / EBITDA | 10.31 | -28.90 | -9.98 | -15.32 |
| Quality | ||||
| ROIC | -27.95% | -41.53% | -12.78% | -21.92% |
| Gross Margin | 100.00% | -12,387.33% | -6,546.17% | -1,007.03% |
| Cash Conversion Ratio | -4.84 | 1.59 | 4.82 | 2.52 |
| Growth | ||||
| Revenue 3-Year CAGR | 27.33% | -57.80% | -36.96% | 4.73% |
| Free Cash Flow Growth | -26.58% | 41.34% | -10.39% | -19.44% |
| Safety | ||||
| Net Debt / EBITDA | -3.25 | 9.37 | 1.29 | 8.80 |
| Interest Coverage | -13.56 | -10.84 | -50.04 | -31.88 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 1,091.45 | 1,099.28 | 2,087.59 | 93.79 |